Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05XSJ
|
|||
| Former ID |
DIB001620
|
|||
| Drug Name |
Asfotase alfa
|
|||
| Synonyms |
SPHEX, BioMep; SPHEX, Enobia; PHEX-based enzyme replacement therapy, BioMep; PHEX-based enzyme replacement therapy, Enobia; X-linked hypophosphatemic rickets therapy, BioMep; X-linked hypophosphatemic rickets therapy, Enobia
Click to Show/Hide
|
|||
| Indication | Genetic disease [ICD-11: 8E02; ICD-10: Q00-Q99] | Approved | [1] | |
| Company |
Enobia Pharma Inc
|
|||
| ADReCS Drug ID | BADD_D00174 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alkaline phosphatase tissue-nonspecific (ALPL) | Target Info | Modulator | [2] |
| KEGG Pathway | Folate biosynthesis | |||
| Metabolic pathways | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathwhiz Pathway | Vitamin B6 Metabolism | |||
| WikiPathways | Endochondral Ossification | |||
| BDNF signaling pathway | ||||
| AGE/RAGE pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01176266) Open-Label Study of Asfotase Alfa in Infants and Children 5 Years of Age With Hypophosphatasia (HPP). U.S. National Institutes of Health. | |||
| REF 2 | Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012 Mar 8;366(10):904-13. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.